system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Aged, Aged, 80 and over, Antigens, CD, Antigens, Differentiation, Myelomonocytic, Antirheumatic Agents, Arthritis, Rheumatoid, Biomarkers, Blood Sedimentation, C-Reactive Protein, Denmark, Disease Progression, Double-Blind Method, Drug Therapy, Combination, Early Diagnosis, Female, Humans, Longitudinal Studies, Macrophages, Male, Middle Aged, Osteoarthritis, Predictive Value of Tests, Radiography, Receptors, Cell Surface, Synovial Fluid, Time Factors, Treatment Outcome.
user
Is soluble macrophage-derived CD163 a marker of disease activity and progression in early rheumatoid arthritis? Context: To investigate the expression of the soluble form of the resident macrophage marker CD163 (sCD163) and its association with core parameters for disease activity, including radiographic progression in early rheumatoid arthritis (RA). In a longitudinal sample set from early RA patients (n=34) we measured plasma levels of sCD163 at initiation of treatment and after 9 months of treatment and correlated levels with disease activity in 28 joints (DAS28), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and total Sharp score (TSS). We also measured plasma levels of sCD163 in 55 healthy volunteers (HV) and in a transverse sample set of chronic (>8 years of disease) RA patients (n=24) and OA patients (n=24) with paired plasma and joint fluid. Early RA patients had significantly higher plasma levels of sCD163 (1.69mg/l (1.42-2.10)) (median (IQR)) at baseline than after 9 months of treatment (1.28mg/l (0.963-1.66), p=0.001), but not significantly changed compared with HV (1.66mg/l (1.22-2.02)). In early RA patients, baseline levels of sCD163, correlated with DAS28, CRP and ESR. Interestingly, sCD163 at 9 months was associated with radiographic progression (TSS) between year 0 and 5 (r=0.468, p=0.02). Levels of sCD163 were higher in RA patients, than in OA patients and higher in SF than in plasma.
assistant
Plasma levels of macrophage derived sCD163 are associated with disease activity and predict radiographic progression in early RA patients, supporting that sCD163 may have a role as a biomarker of disease activity and that resident macrophages are important for joint destruction. Final Decision: yes